GUILFORD, Conn.--(BUSINESS WIRE)--Strong evidence supports the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department. ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026. From a clinical perspective, I have been impressed by the image quality delivered by the ...

Core Insights - The article discusses a prospective study aimed at evaluating the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI [1] Group 1 - The study is designed to assess the practicality of using ultra-low-field portable MRI technology in clinical settings [1] - It focuses on the visualization advantages that contrast enhancement may provide in MRI imaging [1]

Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – January 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, Inc. PROPERTY OF HYPERFINE. ©2026. All rights reserved. B MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For Significantly less expensive, no High-cost and ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Preliminary, Unaudited Financial Results Preliminary, unaudited revenue for the fourth qua. ...

Core Insights - Hyperfine has announced the first analysis indicating that its AI-powered Swoop® portable MRI system is effective in reducing hospital costs and enhancing economic outcomes in acute care settings [1] Company Summary - Hyperfine's Swoop® portable MRI system utilizes artificial intelligence to improve the efficiency and cost-effectiveness of MRI imaging in hospitals [1]

Hyperfine, Inc. (NASDAQ:HYPR – Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 659,270 shares, a decline of 15.6% from the November 30th total of 780,752 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 894,142 shares, the days-to-cover ratio is currently 0.7 days. Based on an average daily volume of 894,142 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1 ...

GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market. ...

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine secures FDA clearance for new DWI sequence, significantly expanding the Swoop® system's clinical capabilities in acute neurological care. ...

Summary of Hyperfine Conference Call Company Overview - **Company**: Hyperfine - **Industry**: Medical Technology (Med Tech) - **Product**: First FDA-cleared portable brain MRI system Key Points and Arguments 1. **Market Opportunity**: Hyperfine estimates a total addressable market of approximately $6 billion, with potential to exceed $15 billion as technology expands into community and primary care settings [2][4][24] 2. **Product Features**: The Swoop scanner operates at 64 millitesla, significantly lower than conventional MRIs (1.5 Tesla), allowing for portability and ease of use in various care settings [3][5] 3. **Clinical and Economic Proposition**: The technology aims to improve access to MRI in critical care units, emergency rooms, and operating theaters, reducing patient transport costs and risks [2][4][13] 4. **Innovation and Development**: Hyperfine has over 200 patents and has developed 11 generations of software, enhancing image quality and operational efficiency [6][7][24] 5. **Regulatory Approvals**: The company has broad FDA clearance for brain imaging across all age groups, positioning it as a first mover in the ultra-low field MRI market [6][18] 6. **Commercial Strategy**: Hyperfine's growth strategy includes expanding into hospital settings, neurology offices, and international markets, with a focus on partnerships and distributor networks [10][22][24] 7. **Financial Performance**: In Q3, Hyperfine reported a 27% increase in revenue, totaling $3.4 million, and a 27% reduction in cash burn sequentially [24][25] 8. **Future Outlook**: The company anticipates a transformative second half of 2025, with strong gross margins and continued innovation in AI-enabled technology [25][26] Additional Important Content 1. **AI Integration**: Hyperfine utilizes AI for image denoising and reconstruction, enhancing the quality of images obtained from the portable MRI system [12][25] 2. **International Expansion**: The company is awaiting regulatory clearance in India, expected to generate commercial revenue by 2026, and has established partnerships for deployment in low-resource settings [18][21][24] 3. **Reimbursement Structure**: Scans performed with the Swoop system are reimbursed under the same codes as conventional MRIs, facilitating adoption in healthcare systems [7][18] 4. **Clinical Studies**: Hyperfine has conducted numerous studies demonstrating the clinical utility of its system, including studies in stroke and emergency departments [14][16] 5. **Distribution Model**: The business model is CapEx-based, with an MSRP of $550,000 for the next-gen Swoop system, including warranties and software upgrades [22][24] This summary encapsulates the key insights from the Hyperfine conference call, highlighting the company's innovative approach to portable MRI technology and its strategic plans for growth and market expansion.